All In Biotech

Drug Trial Radar · NCT05696080

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal Disease.

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

518

Actual

Start

Feb 13, 2023

Primary completion

Feb 16, 2024

Study completion Feb 16, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination within each vaccination group separately.

Conditions

  • Pneumococcal Infection

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • PlaceboBiological

    Saline in each 0.5 mL sterile solution

  • PCV15Biological

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

  • PPSV23Biological

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccinationTime frame: Up to 5 days following each vaccination
  2. Participants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccinationTime frame: Up to 5 days following each vaccination
  3. Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The StudyTime frame: Up to 194 days following Visit 2 (Day 1)
  4. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116Time frame: 30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.

Locations

44 sites in 8 countries. Site status is shown where the registry gives one.

  • Aventiv Research ( Site 0022)

    Mesa, Arizona

  • Indago Research & Health Center, Inc ( Site 0002)

    Hialeah, Florida

  • Triple O Research Institute, P.A ( Site 0011)

    West Palm Beach, Florida

  • SKY Integrative Medical Center/SKYCRNG ( Site 0012)

    Ridgeland, Mississippi

  • Mid Hudson Medical Research ( Site 0008)

    New Windsor, New York

  • Holston Medical Group ( Site 0010)

    Kingsport, Tennessee

  • EmVenio Research ( Site 0018)

    Fort Worth, Texas

  • Wenatchee Valley Hospital ( Site 0019)

    Wenatchee, Washington

  • Holdsworth House Medical Practice ( Site 0402)

    Darlinghurst, New South Wales, Australia

  • Royal Brisbane and Women's Hospital ( Site 0400)

    Brisbane, Queensland, Australia

  • G A Research Associates ( Site 0100)

    Moncton, New Brunswick, Canada

  • Hamilton Medical Research Group ( Site 0107)

    Hamilton, Ontario, Canada

  • Milestone Research Inc. ( Site 0106)

    London, Ontario, Canada

  • Manna Research Mirabel ( Site 0105)

    Mirabel, Quebec, Canada

  • Clinique de médecine Urbaine du Quartier Latin ( Site 0111)

    Montreal, Quebec, Canada

  • Diex Recherche Trois-Rivieres ( Site 0110)

    Trois-Rivières, Quebec, Canada

  • Diex Recherche Victoriavile Inc. ( Site 0102)

    Victoriaville, Quebec, Canada

  • Hospital Dr. Hernán Henríquez Aravena ( Site 1001)

    Temuco, Araucania, Chile

  • Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010)

    Talca, Maule Region, Chile

  • Universidad San Sebastian - Providencia ( Site 1003)

    Providencia, Region M. de Santiago, Chile

  • Centro de Investigaciones Medicas Respiratorias (CIMER) ( Site 1008)

    Santiago, Region M. de Santiago, Chile

  • Centro de Investigacion Clinicadela Universidad Catolica ( Site 1004)

    Santiago, Region M. de Santiago, Chile

  • Universidad de Chile - Hospital Clínico Universidad de Chile-Cardiology ( Site 1006)

    Santiago, Region M. de Santiago, Chile

  • CESFAM Esmeralda ( Site 1009)

    Santiago, Region M. de Santiago, Chile

  • Medical corporation Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic ( Site 0200)

    Kurume, Fukuoka, Japan

  • Shimonoseki Medical Center ( Site 0201)

    Shimonoseki, Yamaguchi, Japan

  • P3 Research - Wellington ( Site 0503)

    Wellington, New Zealand

  • Pacific Clinical Research Network - Rotorua ( Site 0500)

    Rotorua, Bay of Plenty, New Zealand

  • P3 Research - Tauranga ( Site 0507)

    Tauranga, Bay of Plenty, New Zealand

  • CGM Research Trust ( Site 0505)

    Christchurch, Canterbury, New Zealand

  • Pacific Clinical Research Network - Forte ( Site 0501)

    Christchurch, Canterbury, New Zealand

  • P3 Research - Lower Hutt ( Site 0508)

    Lower Hutt, Wellington Region, New Zealand

  • IN VIVO ( Site 0601)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Centrum Medyczne Pratia Bydgoszcz-Centrum Medyczne Pratia Bydgoszcz ( Site 0607)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • MICS Centrum Medyczne Torun ( Site 0606)

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Clinmedica Research Sp. z. o. o. ( Site 0603)

    Skierniewice, Łódź Voivodeship, Poland

  • Centrum Medyczne Medyk ( Site 0602)

    Rzeszów, Podkarpackie Voivodeship, Poland

  • Centrum Medyczne Pratia Katowice ( Site 0604)

    Katowice, Silesian Voivodeship, Poland

  • Clinical Medical Research ( Site 0605)

    Katowice, Silesian Voivodeship, Poland

  • Korea University Anam Hospital ( Site 0305)

    Seoul, South Korea

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.